Glucagon-Like Peptides

Name
Glucagon-Like Peptides
Accession Number
DBCAT001826
Description

Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.

Drugs
DrugDrug Description
LiraglutideA GLP-1 analog used in the management of type 2 diabetes mellitus and prevention of cardiovascular complications associated with diabetes.
TeduglutideA glucagon-like peptide-2 (GLP-2) analog used to treat patients with Short Bowel Syndrome (SBS) who require parenteral nutritional support.
AlbiglutideA GLP-1 agonist used to manage type 2 diabetes mellitus.
TaspoglutideTaspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted...
rGLP-1Investigated for use/treatment in congestive heart failure and diabetes mellitus type 2.
BPI-3016BPI-3016 is under investigation in clinical trial NCT03188848 (Dose Escalating Study of BPI-3016 in Healthy Subjects).
Drugs & Drug Targets
DrugTargetType
LiraglutideGlucagon-like peptide 1 receptortarget
LiraglutideDipeptidyl peptidase 4enzyme
LiraglutideNeprilysinenzyme
LiraglutideSerum albumincarrier
TeduglutideGlucagon-like peptide 2 receptortarget
AlbiglutideGlucagon-like peptide 1 receptortarget